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Proinsulin is an abundant protein that is selectively expressed by pancreatic beta cells and
has been a focus for development of antigen-specific immunotherapies for type 1
diabetes (T1D). In this study, we sought to comprehensively evaluate reactivity to
preproinsulin by CD4 T cells originally isolated from pancreatic islets of organ donors
having T1D. We analyzed 187 T cell receptor (TCR) clonotypes expressed by CD4 T cells
obtained from six T1D donors and determined their response to 99 truncated
preproinsulin peptide pools, in the presence of autologous B cells. We identified 14
TCR clonotypes from four out of the six donors that responded to preproinsulin peptides.
Epitopes were found across all of proinsulin (insulin B-chain, C-peptide, and A-chain)
including four hot spot regions containing peptides commonly targeted by TCR
clonotypes derived from multiple T1D donors. Of importance, these hot spots overlap
with peptide regions to which CD4 T cell responses have previously been detected in the
peripheral blood of T1D patients. The 14 TCR clonotypes recognized proinsulin peptides
presented by various HLA class II molecules, but there was a trend for dominant restriction
with HLA-DQ, especially T1D risk alleles DQ8, DQ2, and DQ8-trans. The characteristics of
the tri-molecular complex including proinsulin peptide, HLA-DQ molecule, and TCR
derived from CD4 T cells in islets, provides an essential basis for developing antigen-
specific biomarkers as well as immunotherapies.
Keywords: antigens, type 1 diabetes, islets, T cell receptors, preproinsulin, epitopes
INTRODUCTION
Type 1 diabetes (T1D) is a disease resulting from dysregulation of adaptive immune responses targeting
pancreatic beta cells (1, 2). A high proportion of T1D patients have HLA-DR4-DQ8 and/or DR3-DQ2
haplotypes (3–7). This strong genetic association within the HLA class II gene locus suggests a crucial
role of CD4 T cells in the development of this disease. Recent studies have demonstrated that CD4 T
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cells reactive to beta cell antigens are present in the islets of organ
donors having T1D (8–11). Some of these T cells target peptides
derived from proinsulin, providing an underlying rationale to
develop proinsulin-specific immunotherapies. A number of
antigen-specific immunotherapies aiming to modulate T1D-
associated T cells, i.e., nanoparticle vaccination, small molecules
or monoclonal antibodies to block formation of the tri-molecular
complex, and infusion of antigen-specific regulatory T cells, require
precise molecular information about peptide-MHC complexes
targeted by T cells (12–19). Hence, identification of not only
epitopes but in addition, the MHC molecules presenting these
peptides, will aid in the development of antigen-specific
immunotherapies targeting T cells associated with the
T1D pathogenesis.
Preproinsulin is selectively and abundantly expressed by
pancreatic beta cells, thereby often being highlighted as a key
autoantigen for T1D. Autoantibodies directed to insulin and
proinsulin are observed in sera from a majority of individuals
developing T1D (20, 21). As evidence of antigens for T cells,
Mallone and colleagues reported that approximately one third of
peptides eluted fromHLA class I molecules expressed by primary
human islets were derived from preproinsulin (22). Furthermore,
we and others have isolated T cells specific to preproinsulin in
the islets and peripheral blood of individuals having T1D (8–10,
23–27). In particular, Mannering and colleagues identified CD4
T cell clones reactive to C-peptide, all of which recognized the
peptide presented by HLA-DQ and/or DQ8-trans, in an islet
sample from an organ donor having T1D (8). They subsequently
demonstrated T cell responses to C-peptide in the peripheral
blood of T1D patients and consistent with their islet study, the
majority of C-peptide-reactive T cell clones isolated from
peripheral blood samples were restricted with HLA-DQ
molecules as well (27). Kent and colleagues also isolated
preproinsulin-reactive T cell lines from islet samples of
multiple T1D organ donors (9). In our previous study, we
identified T cell receptor (TCR) clonotypes expressed by T
cells in the islets of T1D organ donors and found three
clonotypes specific to insulin B-chain and C-peptide presented
by HLA-DQ8 and DQ8-trans (10). Thus, a number of studies
have demonstrated the presence of preproinsulin-reactive T cells
in the islets of individuals having T1D. In this study, we aimed to
comprehensively analyze and characterize tri-molecular
complexes composed of preproinsulin peptide, HLA, and TCR
derived from CD4 T cells in the islets of T1D organ donors.
Recent improvements in sequencing technologies have
facilitated the identification of T and B cell receptor sequences
in a high-throughput manner (28, 29). It is desirable to
determine antigen specificity of these immunoreceptors and
indeed, there has been remarkable progress in developing high-
throughput strategies to identify antigens recognized by these
antigen receptors (30–37). Unlike analysis of B cell antigens, the
fact that MHC molecules participate in the recognition of
epitopes by TCRs makes it more complicated to identify T cell
targets. Immortalized cell lines expressing TCR clonotypes of
interest promoted feasibility of directly evaluating reactivity to
specific peptide-MHC complexes. Hence, we recently developed
a multiplex assay system that can simultaneously assess reactivity
of a number of TCR transductant cell lines (38). Multiplex efforts
spare samples and reagents necessary for the assay, thereby
allowing analysis of reactivity to hundreds of peptides within a
relatively short period of time. In this current study, we used this
multiplex assay system to test responses against preproinsulin
peptides in the presence of autologous B cells transformed with
Epstein-Barr virus (EBV) by islet-derived TCR clonotypes
obtained from the residual islets of T1D organ donors. The
peptide library is composed of 12-15mers of peptides that are
generated from the natural form of preproinsulin. Thus, we
evaluated reactivity to preproinsulin epitopes presented by all
possible HLA class II molecules in a deep and comprehensive
manner. Furthermore, using antigen presenting cell lines that
exclusively express a single HLA, we identified HLA class II
molecules presenting peptides to individual preproinsulin-
reactive TCR clonotypes. Here we report the molecular
elements involved in the immune-recognition of preproinsulin
peptides by islet-derived CD4 T cells.
RESULTS AND DISCUSSION
Screening of Islet CD4 T Cell-Derived T
Cell Receptors for the Response to
Preproinsulin Peptides
We analyzed 187 TCR clonotypes derived from 166 clonal CD4
T cells in the islets of six T1D organ donors for specificity to
preproinsulin (Table 1, Supplementary Table 1). These TCR
clonotypes were selected for analysis because they were detected
from multiple cells or have a specific V-gene motif such as
TRAV13-1, TRAV26-1, or TRAV38-2, which are preferentially
used by CD4 T cells specific to amino acids 9-23 of insulin B
chain (10, 26, 39). We expressed each TCR clonotype in a 5KC
murine T-hybridoma cell line, which has an added activation
reporter driven by the production of nuclear factor of activated T
cells (NFAT) (38), to test the response to 99 peptide pools
containing 12-mer to 15-mer of peptides derived from
preproinsulin (Supplementary Table 2). To detect responses
against peptides presented by any possible HLA molecules
expressed by a given donor, autologous EBV-transformed B
cells were used. Screening of 187 TCR clonotypes identified 14
TCRs (7.5%), derived from four donors, that responded to
preproinsulin peptide pools. These 14 TCR transductants
expressed a fluorescent reporter, ZsGreen-1, when cultured
with particular peptide pools (Figure 1). As the peptide
concentration used for the screening was supraphysiologic to
maximize the detection of preproinsulin-reactive TCRs, some
TCR transductants responded to multiple peptide pools that
contain peptides sharing the same portion of amino acid
sequences. To determine an optimal epitope region, we newly
synthesized 15-mer peptides contained in top 4 or 5 peptide
pools that most efficiently stimulated TCR transductants
(Supplementary Figure 1, Supplementary Table 3) and used
those peptides to evaluate responses by each TCR transductant.
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TCR transductants reacted with peptide pools in a dose-
dependent manner (Figure 2), and thus we identified the
region of peptide containing the optimal epitope for each TCR
clonotype. Overall, we found seven, four, and three epitopes
recognized by the 14 TCR clonotypes in insulin B-chain, C-
peptide, and A-chain, respectively, including three TCRs, 6.H9,
20.D11, and 8.E3, that were previously found by screening of the
response to overlapping preproinsulin peptides (10). Altogether,
we identified 14 preproinsulin-reactive TCR clonotypes in the
islets of four out of six T1D organ donors studied.
Identification of Peptide-MHC Complexes
Targeted by Proinsulin-Reactive T Cell
Receptor Clonotypes
We next aimed to identify HLA molecules presenting proinsulin
peptides to the 14 TCR clonotypes. We used the newly
synthesized 15-mer peptides that were identified as a region
containing an optimal epitope for each TCR transductant. Our
strategy was to test the response to the cognate peptide in the
presence of K562 antigen presenting cells expressing HLA
molecules identical to those of the TCR donor. K562 cells do
not express endogenous HLA class II molecules, allowing us to
examine the response restricted only by the introduced HLA.
We first generated three K562 cell lines expressing HLA-DR
(DRB1), DQ, or DP molecules matching each donor and used
them as antigen presenting cells. Once narrowing the presenting
HLA molecules to DR, DQ, or DP-derived molecules, we further
examined the responses by TCR transductants in the presence
of K562 cell lines that individually express any possible
combination of HLA-DR, DQ, or DP molecules including cis-
and trans-combinations of HLA-DQA1 and DQB1 or DPA1
and DPB1 molecules. This way, we identified one or more HLA
molecules presenting the cognate peptide to each TCR. For
example, the 95.A9-1 TCR clonotype was derived from donor
nPOD 6472, who had the DR3 and DR4 haplotypes (Table 1).
The 95.A9-1 transductants responded to a cognate peptide,
preproinsulin 87-101, when cultured with K562 cells co-
transduced with DRA1*01:01, DRB1*04:04, and DRB1*03:01,
but not with those transduced with the DQ or DP alleles (Figure
3A, left panel). The 95.A9-1 TCR transductant cells were
further examined for the response to peptides in the presence
of K562 cells transduced with DRA1*01:01 along with either
DRB1*04:04 or DRB1*03:01 and were activated only when
co-cultured with cells expressing DRB1*04:04 (Figure 3A,
center panel). Lastly, we confirmed that the 95.A9-1 cells
responded to the cognate peptide in the presence of K562 cells
expressing the determined HLA in a dose-dependent manner
(Figure 3A, right panel). Thus, we determined that 95.A9-1 is
reactive to preproinsulin 87-101 presented by DRA1*01:01-
DRB1*04:04 (DR4).
Using the same strategy, we determined HLA molecules
presenting a cognate peptide to all individual TCR clonotypes
except one, 55.C10. Figures 3–5 show the results (left panels:
determining HLA-DR, DQ, or DP, center panels: determining
HLA-alpha and -beta combinations, right panels: dose-response
assessment) for five DR- (Figure 3), seven DQ- (Figure 4), and
one DP (Figure 5)-restricted TCRs.
There was one TCR clonotype, 55.C10, that did not respond to
a cognate peptide in the presence of any K562 cell lines expressing
the donor’s HLA-DR, DQ, and DP molecules (Figure 6A).
To investigate which HLA genes restrict 55.C10, we tested the
response by TCR transductants in the presence of autologous B
cells and antibodies against HLA-DR, DQ, or DP and found that
anti-HLA-DR antibodies suppressed the response (Figure 6B).
The TCR is likely to recognize the peptide presented by HLA-DR,
but K562 cells expressing molecules derived from the DRB1 allele
was not able to stimulate the TCR transductant, suggesting that
another DR beta chain such as those derived from the DRB3,
DRB4, or DRB5 genes may be involved in the presentation of the
peptide. The donor of TCR 55.C10, nPOD 6414, had DR3 and
DR9 haplotypes, which are linked to functional DRB3 and DRB4
genes, respectively, but DRB5 alleles of both haplotypes are
pseudogenes. After determining alleles of DRB3 and DRB4 of
the donor (i.e., DRB3*01:01 and DRB4*01:01), we generated K562
cells transduced with these allelic variants and found that the
55.C10 TCR transductants were reactive to the peptide presented
by HLA-DRB4*01:01 (Figures 6C, D). As CD4 T cells specific to
another proinsulin peptide presented by DRB4*01:01 have been
observed in the blood of T1D patients (40), there may be disease-
specific epitopes presented by HLA-DRB3 and DRB4 alleles that
are linked to the T1D-susceptible HLA-DR4-DQ8 and/or DR3-
DQ2 haplotypes.
TABLE 1 | HLA class II alleles of T1D organ donors and the numbers of T cells analyzed.
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*Nomenclatures in parentheses indicate HLA serotypes.
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Table 2 as well as Figure 7A summarize peptides and
presenting HLA molecules targeted by individual TCR
clonotypes. Of note, peptides recognized by multiple TCRs,
such as preproinsulin 33-47 recognized by 6.H9 and 20.D11,
preproinsulin 36-50 recognized by 23.G8 and 55.B3, and
preproinsulin 72-87 recognized by 8.E3 and 53.A4-1, were
presented by the same HLA gene products (i.e., DR or DQ)
but sometimes different allele products. In addition, it was noted
that several TCR clonotypes, 23.G8, 6.H9, 8.E3, 53.A4-1, and
6.G4, recognized cognate peptides presented by several HLA
class II molecules, albeit with different levels of response,
implying that the same peptides can be presented by multiple
HLA molecules and induce various levels of T cell activation.
These different levels of responsiveness are likely to be the
combined outcome from differential peptide to HLA binding
affinity, and TCR to peptide-MHC complex affinity. Intensity of




























































































































































































































































FIGURE 1 | Screening for the response to a preproinsulin truncated peptide library. 5KC T-hybridoma cells expressing ZsGreen-1 upon activation were used to
express each TCR clonotype. TCR transductants were cultured with 99 truncated peptide pools containing 12-, 13-, 14-, and 15-mers of peptides ending at the
same position of preproinsulin in the presence of autologous EBV-transformed B cells. After overnight culture, cells were evaluated for ZsGreen-1 expression by flow
cytometry. Percentages of ZsGreen-1-positive cells in response to each peptide pool are shown for 14 TCR transductants that responded to one or more peptide pools.
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signals provided through the TCR engagement is a major factor
determining T cell phenotype as well as their fate (41, 42). It will
be important to elucidate how T cells determine their responses
when receiving different levels of TCR signaling through epitopes
presented by multiple HLA class II molecules having
different affinities.
Overall, we identified five DRB1, seven DQ, one DP, and one
DRB4-restricted TCR clonotypes that recognize proinsulin
peptides (Figure 7B). It has been suggested that DRB1-
restricted TCR repertoires are generally the largest among
those expressed by CD4 T cells. While the number of
proinsulin-specific clonotypes identified in our study is small,
there was a noteworthy trend that the proportion of DR-
restricted TCR clonotypes was not as high as previously
reported frequencies of DR-restricted TCRs in virus-reactive
repertoires (43–45), and rather DQ-restricted TCRs were more
predominant. Future studies investigating HLA restriction of a
large number of T cells from the islets of patients and at-risk
individuals are expected to confirm this trend.
Responsiveness to Proinsulin Epitopes
by Autoreactive T Cells
The responsiveness to peptides differed by individual TCRs
(Figures 3–5, right panels). To compare response levels of








































































































































































































































FIGURE 2 | Determining optimal peptides. TCR transductants that responded to multiple peptide pools in the screening were tested for the response to newly
synthesized 15-mer peptides contained in individual peptide pools in the presence of autologous EBV-transformed B cells, and were evaluated for ZsGreen-1
expression by flow cytometry. Experiments were independently repeated three times, and mean values ± standard error of the mean are shown.
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preproinsulin-reactive TCRs with those of TCRs unrelated to the
T1D pathogenesis, we generated two TCR transductant cell lines
using the same method to make islet TCR transductants. First, we
used an influenza virus-reactive TCR clonotype, HA1.17. The
HA1.17 TCR transductants reacted to a cognate influenza peptide
presented by either HLA-DR1 or DR4 starting at only one
nanomolar (Supplementary Figure 2A). Next, we evaluated the
sensitivity of a gliadin-specific TCR, 489, to the native and
deamidated forms of peptides in our transductant system. It is
well-appreciated that alpha-gliadin peptides that undergo
deamidation (Q!E) are target antigens for T cells involved in
the pathogenesis of celiac disease, an autoimmune disease caused
by gluten intake in disease-sensitive individuals (46, 47). As
expected, the 489 TCR transductants responded to the
deamidated peptide presented by DQ8 more sensitively than the
native alpha-gliadin peptide (Supplementary Figure 2B). Several
proinsulin-reactive TCR clonotypes including two restricted by
HLA-DP and DRB4 showed comparable levels of responses to
their cognate peptides compared to those of the influenza-specific
HA1.17 and the gliadin-specific 489 TCRs (Figure 7C). The
expression levels of HLA-DP and DRB4 molecules on antigen
presenting cells are reported to be lower than that of HLA-DRB1
molecules (45, 48), which may influence selection and
differentiation of self-reactive T cells restricted by HLA
molecules with lower cell surface expression, such as HLA-DP.
On the other hand, responsiveness of several preproinsulin-
specific clonotypes was lower than those of the HA1.17 and 489
TCRs (Figure 7C). In particular, the 6.G4 and 23.G8 TCRs needed
excessive amounts of peptides to be activated. There is a possibility
that biological targets for these TCR clonotypes exhibiting weaker
responses could be neoepitopes such as those receiving post-
translational modifications and products resulting from
alternative splicing. Alternatively, antigens activating T cells
expressing these TCRs could be unrelated to proinsulin or even
other islet antigens, such as those derived from microbes, and the






FIGURE 3 | Preproinsulin-reactive TCR clonotypes restricted by HLA-DR. TCR transductants, (A) 95.A9-1, (B) 23.F7, (C) 23.G8, (D) 6.H11, (E) 55.B3, were
cultured with cognate peptides in the presence of designated antigen presenting cells, followed by assessment of ZsGreen-1 expression by flow cytometry. Left
panels: TCR transductants were cultured with (blue bars) or without (black bars) cognate peptides in the presence of autologous EBV-transformed B cells generated
from spleen cells of (A) nPOD 6472, (B, C) nPOD 6342, (D) nPOD 6323, or (E) nPOD 6414, or K562 cells transduced with DR, DQ, or DP alleles based upon
their HLA genotype in Table 1. Culture wells containing an anti-CD3 monoclonal antibody were included as a positive control (red bars). Center panels: TCR
transductants were cultured with (blue bars) or without (black bars) cognate peptides in the presence of K562 cells transduced with individual DR alleles based upon
their HLA genotype in Table 1. Right panels: TCR transductants were cultured with different concentrations of cognate peptides in the presence of K562 cells
transduced with (A) DRA1*01:01 and DRB1*04:04; (B) DRA1*01:01 and DRB1*01:01; (C) DRA1*01:01 and DRB1*01:01 (black triangles), or DRA1*01:01 and
DRB1*04:01 (white triangles); (D) DRA1*01:01 and DRB1*04:02; (E) DRA1*01:01 and DRB1*09:01. Experiments in left panels were performed once. All remaining
experiments in center and right panels were independently repeated three times, and mean values ± standard error of the mean are shown.
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Reactivity to Proinsulin and Islet Tissues
Tovalidate tissue specificity,we further tested the response towhole
proinsulinand tissue lysatesmade fromprimaryhuman isletsby the
14TCRtransductants reactive toproinsulinpeptides.All except two
TCRs, 6.G4 and 23.G8, which showed only marginal responses to
their cognate peptides, responded to islet lysates (Figure 7D).
Consistent with undetectable reactivity to islet lysates, 6.G4 but
not 23.G8 weakly responded to proinsulin. These observations are
compatible with the possibility of cross-reactivity to proinsulin.
Intensities of responses to cognate peptides are not necessarily
associatedwith those towhole proinsulin and islet lysates, and some








FIGURE 4 | Preproinsulin-reactive TCR clonotypes restricted by HLA-DQ. TCR transductants, (A) 20.D11, (B) 19.A4, (C) 6.G4, (D) 6.H9, (E) 8.E3, (F) 53.A4-1,
(G) 56.B1, were cultured with cognate peptides in the presence of designated antigen presenting cells, followed by assessment of ZsGreen-1 expression by flow
cytometry. Left panels: TCR transductants were cultured with (blue bars) or without (black bars) cognate peptides in the presence of autologous EBV-transformed B
cells generated from spleen cells of (A, B) nPOD 6342, (C–E) nPOD 6323, or (F, G) nPOD 6414, or K562 cells transduced with DR, DQ, or DP alleles based upon
their HLA genotype in Table 1. Culture wells containing an anti-CD3 monoclonal antibody were included as a positive control (red bars). Center panels: TCR
transductants were cultured with (blue bars) or without (black bars) cognate peptides in the presence of K562 cells transduced with individual DQ alleles based upon
their HLA genotype in Table 1. Right panels: TCR transductants were cultured with different concentrations of cognate peptides in the presence of K562 cells
transduced with (A, B) DQA1*03:01 and DQB1*03:02; (C–E) DQA1*03:01 and DQB1*03:02 (black triangles), or DQA1*05:01 and DQB1*03:02 (white triangles);
(F) DQA1*05:01 and DQB1*02:01 (black triangles), DQA1*03:03 and DQB1*02:01 (white triangles), DQA1*03:03 and DQB1*02:02 (black inverted triangles), or
DQA1*05:01 and DQB1*02:02 (white inverted triangles); (G) DQA1*05:01 and DQB1*02:01 (black triangles), or DQA1*05:01 and DQB1*02:02 (white triangles).
Experiments in left panels were performed once. All remaining experiments in center and right panels were independently repeated three times, and mean values ±
standard error of the mean are shown.
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whole proinsulin rather than islet lysates. These discrepancies may
be caused by difference between optimal epitopes and peptides
formed islet cells or antigen presenting cells.
Citrullinated Insulin B-Chain Peptides Do
Not Enhance T Cell Responses
Five out of 14 proinsulin-reactive TCR transductants responded to
peptides located in the latter portion of insulin B-chain, and the
majority of these TCRs showed relatively weak responsiveness to
the native insulin peptides. Citrullination converts arginine to
citrulline and is an important post-translational modification of
self-antigens in autoimmune diseases such as Rheumatoid arthritis
and T1D (49–51). To begin to examine the potential for
neoepitopes within proinsulin, we investigated antigenicity of a
citrullinated insulin B-chain peptide. We tested the five insulin B-
chain-reactive TCR transductants for response to the citrullinated
and the native forms of insulin B-chain peptides. All TCR
transductants except 23.G8, that reacted with the cognate 15-mer
peptide very weakly (Figure 3C), responded to the native insulin B-
chain peptide, but citrullination of the peptide did not induce
stronger responses in any TCRs (Figure 8). Further studies to
identify biological epitopes, especially for TCRs with low responses
to the natural form of proinsulin, such as 23.G8, will be important
to understand the mechanisms of initiating and driving anti-
islet autoimmunity.
In the current study, we identified 11 new proinsulin-reactive
TCR clonotypes in addition to three clonotypes found in our
previous study that screened reactivity to ten overlapping
preproinsulin peptides (10), and thus 14 TCR clonotypes were
characterized for preproinsulin specificity and HLA restriction.
The use of a truncated peptide library containing 99
preproinsulin peptide pools and autologous EBV-transformed
FIGURE 5 | Preproinsulin-reactive TCR clonotypes restricted by HLA-DP. The TCR 23.G6 transductant was cultured with cognate peptides in the presence of
designated antigen presenting cells, followed by assessment of ZsGreen-1 expression by flow cytometry. Left panel: The 23.G6 TCR transductants were cultured
with (blue bars) or without (black bars) cognate peptides in the presence of autologous EBV-transformed B cells generated from spleen cells of nPOD 6342, or K562
cells transduced with DR (DRA1*01:01, DRB1*04:01, DRB1*01:01), DQ (DQA1*03:01, DQA1*01:01, DQB1*03:02, DQB1*05:01), or DP (DPA1*01:03, DPB1*04:01)
alleles. Culture wells containing an anti-CD3 monoclonal antibody were included as a positive control (red bars). Center panel: The 23.G6 TCR transductant was
cultured with (blue bars) or without (black bars) cognate peptides in the presence of K562 cells transduced with a DP gene combination, DPA1*01:03 and
DPB1*04:01. Right panel: The 23.G6 TCR transductant was cultured with different concentrations of cognate peptides in the presence of K562 cells transduced with
DPA1*01:03 and DPB1*04:01. The experiment in the left panel was performed once. Experiments in the center and right panels were independently repeated three
times, and mean values ± standard error of the mean are shown.
A B
DC
FIGURE 6 | Preproinsulin-reactive TCR clonotypes restricted by HLA-DRB4. (A) The 55.C10 TCR transductant was cultured with (blue bars) or without (black bars)
cognate peptides in the presence of autologous EBV-transformed B cells generated from spleen cells of nPOD 6414, or K562 cells transduced with DR
(DRA1*01:01, DRB1*03:01, DRB1*09:01), DQ (DQA1*05:01, DQA1*03:03, DQB1*02:01, DQB1*02:02), or DP (DPA1*01:03, DPA1*01:04, DPB1*04:01,
DPB1*15:01) alleles. Culture wells containing an anti-CD3 monoclonal antibody were included as a positive control (red bars). (B) The 55.C10 TCR transductant was
cultured with (green bars) or without (black bars) cognate peptides in the presence or absence of anti-DR, -DQ, or -DP antibodies. Autologous nPOD 6414 EBV-
transformed B cells were used as antigen presenting cells. (C) The 55.C10 TCR transductant was cultured with (blue bars) or without (black bars) cognate peptides
in the presence of K562 cells transduced with DRB3 (DRA1*01:01 and DRB3*01:01) or DRB4 (DRA1*01:01 and DRB4*01:01) alleles. (D) The 55.C10 TCR
transductant was cultured with different concentrations of cognate peptides in the presence of K562 cells transduced with DRA1*01:01 and DRB4*01:01.
Experiment in panels (A, B) were performed once. All remaining experiments in panels (C, D) were independently repeated three times, and mean values ± standard
error of the mean are shown.
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B cell lines facilitated our ability to identify these additional TCR
clonotypes. Epitopes were found in B-chain, C-peptide, and A-
chain regions, and there were regions that contained multiple
epitopes recognized by TCRs derived from different donors
(Table 2, Figure 7A). Some of these epitopes were identified as
targets for islet-derived CD4 T cell clones observed in previous
studies by others (8, 9). Overall, there are several peptide regions
spanning about 20 amino acids, i.e. preproinsulin 33-53 (insulin
B-chain), preproinsulin 55-71 (C-peptide), preproinsulin 72-90
(C-peptide), preproinsulin 86-101 (A-chain), that are commonly
targeted by CD4 T cells in the islets of individuals having T1D.
Inflammatory responses by CD4 T cells to these “hot spot”
regions have previously been observed in peripheral blood
samples of T1D patients (26, 27, 52–55). While it is unknown
whether CD4 T cells reactive to the preproinsulin hot spots in the
blood are clonally identical to those in the islets, it is noteworthy
that the same antigen specificities have been confirmed in blood
and islets.
It will be important to determine binding motifs as well as
affinity of the epitopes to the restricting HLA molecules as these
elements are essential to determine responsiveness of T cells and
to develop therapies targeting peptide-MHC complexes. To
begin, we conducted a computational simulation analysis to
predict core epitope sequences using the Immune Epitope
Database (IEDB) MHC-II Binding Prediction online tool
(http://tools.iedb.org/mhcii/), which allows us to use multiple
in silico prediction models. A number of simulations predicted
identical amino acid motifs as a core epitope for each proinsulin-
reactive clonotype (Supplementary Table 4). Further efforts
validating binding affinities and T cell reactivities to these
predicted epitopes are desired in the future.
All HLA-DR, DQ, and DP molecules were used to present
peptides to proinsulin-reactive TCR clonotypes. However,
there was a trend of restriction with HLA-DQ, particularly
the T1D risk alleles, DQ8, DQ2, or DQ8-trans (Table 2,
Figure 7A). Mannering and colleagues also reported that
this preferred restriction with risk DQ alleles was observed
in C-peptide-specific CD4 T cells in the blood (27). Our study
extends this finding to islet-derived TCRs specific to other
regions of proinsulin. Future studies to determine antigen
specificity outside of preproinsulin (e.g., glutamic acid
decarboxylase, zinc transporter 8, islet antigen 2) will clarify
whether the trend of DQ restriction is a general feature of TCR
clonotypes expressed by T1D-associated CD4 T cells.
Additionally, it is important to elucidate the mechanisms by
which HLA-DQ is preferentially used to present epitopes to T
cells reactive to proinsulin and potentially other islet antigens.
Whether this is a global phenomenon across patients or
patient-specific will help design and personalize immune
therapies to preserve endogenous beta-cell function in T1D.
Notably, there is a therapy (methyldopa) being tested that
specifically blocks self-antigen presentation by DQ8 and
subsequent autoreactive T cell responses (12). Our results
also indicate that antigen specific immunotherapies with
insulin, should give strong consideration to including A-
chain, B-chain, and C-peptide (e.g., all of proinsulin) as
there are islet-derived CD4 T cell epitopes within all of
these regions.
In conclusion, we identified 14 proinsulin-specific TCR
clonotypes expressed by CD4 T cells in the islets of four out of
six organ donors having T1D. These TCRs were restricted by
various HLA class II molecules, but there was a trend of using
T1D-risk conferring HLA-DQ molecules. There are four hot
spots within proinsulin that contain epitopes preferentially
targeted by the responding islet TCRs, which overlapped with
antigenic regions recognized by T cells in the peripheral blood
TABLE 2 | HLA class II alleles of T1D organ donors and the numbers of T cells analyzed.
nPOD Donor TCR ID Peptide Peptide Sequence Region in Proinsulin HLA*#
6342 23.F7 PPI:24-38 AFVNQHLCGSHLVEA B-chain DRB1*01:01 (DR1)
6342 23.G6 PPI:29-43 HLCGSHLVEALYLVC B-chain DPA1*01:03-DPB1*04:01 (DP4)
6323 6.H9 PPI:33-47 SHLVEALYLVCGERG B-chain DQA1*03:01-DQB1*03:02 (DQ8) DQA1*05:01-DQB1*03:02 (DQ8-trans)
6342 20.D11 PPI:33-47 SHLVEALYLVCGERG B-chain DQA1*03:01-DQB1*03:02 (DQ8)
6342 23.G8 PPI:36-50 VEALYLVCGERGFFY B-chain DRB1*04:01 (DR4), DRB1*01:01 (DR1)
6414 55.B3 PPI:37-51 EALYLVCGERGFFYT B-chain DRB1*09:01 (DR9)
6414 56.B1 PPI:40-54 YLVCGERGFFYTPKT B-chain DQA1*05:01-DQB1*02:01 (DQ2.5)
DQA1*05:01-DQB1*02:02
6342 19.A4 PPI:55-69 RREAEDLQVGQVELG (RR) C-peptide DQA1*03:01-DQB1*03:02 (DQ8)
6414 55.C10 PPI:58-72 AEDLQVGQVELGGGP C-peptide DRB4*01:01 (DR53)
6323 8.E3 PPI:72-87 PGAGSLQPLALEGSLQ C-peptide DQA1*05:01-DQB1*03:02 (DQ8-trans)
DQA1*03:01-DQB1*03:02 (DQ8)




6323 6.G4 PPI:86-100 LQKRGIVEQCCTSIC (B-KR) A-chain DQA1*05:01-DQB1*03:02 (DQ8-trans)
DQA1*03:01-DQB1*03:02 (DQ8)
6472 95.A9-1 PPI:87-101 QKRGIVEQCCTSICS (B-KR) A-chain DRB1*04:04 (DR4)
6323 6.H11 PPI:94-108 QCCTSICSLYQLENY A-chain DRB1*04:02 (DR4)
*Nomenclatures in parentheses indicate HLA serotypes.
#HLA allele combinations recognized by the TCR most efficiently are shown in bold.
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of T1D patients. T cell antigen specificity to these proinsulin
regions provide an avenue for developing biomarkers in the
peripheral blood that mirror the islets. The level of T cell
response to proinsulin epitopes was lower than that observed
with an influenza-specific TCR, but over half of the TCRs
responded to native proinsulin peptides as comparably as a
level of optimal response exhibited by a TCR specific in
another autoimmune disease (celiac disease). Biological
targets for the TCRs with low responses may be neoepitopes





FIGURE 7 | Characteristics of proinsulin-specific TCR clonotypes. (A) Location of epitopes in preproinsulin and restricting HLA molecules are mapped. Red, blue,
green, and yellow bars represent epitopes for TCR clonotypes restricted by HLA-DRB1, DQ, DP, and DRB4. (B) Numbers of preproinsulin-reactive TCR clonotypes
restricted by HLA-DRB1, DQ, DP, and DRB4. Preproinsulin-reactive TCR clonotypes derived from individual nPOD donors are shown separately by HLA restriction.
(C) EC50 values of responses by preproinsulin-reactive TCR clonotypes are shown separately by HLA restriction. EC50 values of responses by HA.1.17 to the
cognate influenza peptide (black line) and 489 to the deamidated alpha-gliadin peptide (blue line) are included for reference. (D) Responses to proinsulin and human
islet lysates by TCR transductants reactive to proinsulin peptides. TCR transductants were cultured with K562 cells expressing cognate HLA molecules pulsed with
proinsulin (blue bars) or islet lysates (red bars), or without antigens (black bars). After overnight culture, ZsGreen-1 expression was evaluated by flow cytometry.
Experiments were independently repeated twice, and mean values ± standard error of the mean are shown. EC50 values of responses to cognate peptides (white
diamond symbols) are included for reference.
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MATERIALS AND METHODS
T Cell Receptor Transductants
TCR sequences were identified as described previously (10). TCR
transductants were generated using a recently published protocol
(38). Briefly, 5KC T-hybridoma cells (56) were transduced with a
NFAT-driven fluorescent reporter, ZsGreen-1, along with the
human CD4 gene with two amino acid mutations at positions
40 (glutamine to tyrosine) and 45 (threonine to tryptophan) that
increase binding to MHC molecules (57) (the retroviral vector is
available from addgene, plasmid ID 162745) using a standard
spinfection protocol with viral supernatant produced from
phoenix-eco cells (ATCC CRL-3214) (58). Cells were also
transduced with a combination of two fluorescent protein genes
(addgene plasmid ID 153423, 153424, 153524, 153426, 153427,
153428) as an identifier of each TCR. We then transduced each
5KC cell line expressing a specific combination of fluorescent
proteins with a retroviral vector encoding a chimeric TCR alpha
gene followed by a porcine teschovirus-1 2A (P2A) peptide and a
chimeric TCR beta gene (58).
Screening of T Cell Receptor
Transductants for Reactivity
to Preproinsulin
Up to eight TCR transductants (20,000 cells per line) expressing
different combinations of fluorescent proteins were pooled and
cultured with a preproinsulin truncated peptide pool in the
presence of autologous B cells transformed with EBV (100,000
cells per well) in a well of round-bottom 96-well-plates. The
preproinsulin truncated peptide pools were purchased from
Mimotopes (Mulgrave, Australia) as pools of four crude
peptides containing 3-7 mg peptides per pool. Each peptide
pool was dissolved in 250 µl 80% dimethylsulfoxide/20% water,
and 2 µl of dissolved peptide pool was added in a culture well
containing total 200 µl media; thus the peptide concentration
was approximately 200 µg/ml. Peptide sequences contained in
each pool are shown in Supplementary Table 2. Autologous
EBV-transformed B cell lines were made from spleen cells of
individual islet donors using a standard protocol (59). Cultured
cells were harvested next day and analyzed for expression of
ZsGreen-1 in each TCR transductant line using a flow cytometer
(Cytoflex, Beckman Coulter) and FlowJo (BD) (38). An example
of gating strategy is shown in Supplementary Figure 3. Cells
cultured in the presence or absence of 5 µg/ml of anti-mouse
CD3ϵ antibody (Clone 125-2C11, BD) were included in the
assay as positive and negative controls, respectively. The
threshold for positive ZsGreen-1 expression was determined
such that the majority of cells in negative control wells for all
TCR transductants in a same pool becomes negative
(Supplementary Figure 3). When the proportion of ZsGreen-
1-positive cells in a negative control culture well exceeded 20% or
in a positive control culture was lower than 50%, the TCR
clonotypes were excluded from analysis, resulting in total 187






FIGURE 8 | Responses to citrullinated and native insulin B-chain peptides. TCR transductants, (A) 6.H9, (B) 20.D11, (C) 55.B3, (D) 23.G8, (E) 56.B1, were
cultured with different concentrations of insulin B-chain peptide (SHLVEALYLVCGE-R-GFFYTPK) (black symbols) or that with citrullination (SHLVEALYLVCGE-Cit-
GFFYTPK) (white symbols) in the presence of K562 cells expressing the following HLA molecules for each TCR clonotype: (A) DQ8 (DQA1*03:01-DQB1*03:02)
(triangles) and DQ8T (DQA1*05:01-DQB1*03:02) (inverted triangles); (B) DQ8 (DQA1*03:01-DQB1*03:02) (triangles); (C) DR9 (DRA1*01:01-DRB1*09:01) (triangles);
(D) DR4 (DRA1*01:01-DRB1*04:01) (triangles); (E) DQ2 (DQA1*05:01-DQB1*02:01) (triangles) and (DQA1*05:01-DQB1*02:02) (inverted triangles). All experiments
were independently repeated three times, and mean values ± standard error of the mean are shown.
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Determining Optimal Epitope Regions
For TCR transductants that responded to more than one
truncated peptide pools in the screening, responses against
lower amounts of truncated peptide pools (x10, x100, and
x1,000 dilutions of peptide solutions used for the screening)
were examined to identify the most preferred pools
(Supplementary Figure 1). 15-mer peptides contained in top 4
or 5 peptide pools that most efficiently stimulated individual
TCR transductants were newly synthesized by Genemed
synthesis (San Antonio, USA) (Supplementary Table 3). TCR
transductants (20,000 cells per well) were cultured with different
concentrations (10 nM, 100 nM, 1 µM, 10 µM, and 100 µM) of
peptides in the presence of autologous EBV-transformed B cell
lines (100,000 cells per well). After overnight culture, cells were
harvested and analyzed for ZsGreen-1 expression using a flow
cytometer (Cytoflex, Beckman Coulter) and FlowJo (BD) (38).
HLA Typing
HLA-DRB1, DQA1, DQB1, DPA1, and DPB1 alleles were
determined using DNA samples extracted from spleen cells of
each donor by the Barbara Davis Center Autoantibody/HLA
Core Facility (https://medschool.cuanschutz.edu/barbara-davis-
center-for-diabetes/service-centers/autoantibody-hla-service-
center). To determine DRB3 and DRB4 alleles of the donor
nPOD 6414, we PCR-amplified 273-294 bp fragments in which
96-185 bp were overlapped with adjacent fragments at each end
using sets of primers as shown in Supplementary Table 5. The
amplicons were connected to Illumina adaptors by 8 cycles of




ATCT), followed by sequencing on a NovaSEQ sequencer
(Illumina). Contig sequences were blasted to the IMGT/HLA
database (https://www.ebi.ac.uk/Tools/services/web_ncbiblast/
toolform.ebi?tool=ncbiblast&context=nucleotide&database=
imgthla) to identify alleles of DRB3 and DRB4 genes.
HLA Transductants
Two types of antigen presenting cells were generated using the
retroviral or lentiviral expression system. For the initial analysis
to determine HLA-DR, DQ, or DP (experiments shown in left
panels of Figures 3–5, and 6A), retroviral vectors encoding a
puromycin resistance gene along with a first set of DRA1-P2A-
DRB1, DQA1-P2A-DQB1, or DPA1-P2A-DPB1 gene cassette
were generated for each donor, and transduced into K562 cells
(ATCC CCL-243) using a standard spinfection protocol with
viral supernatant produced from 293T cells (ATCC CRL-3216)
(58), followed by sorting of cells stained with anti-HLA-DR
antibody conjugated with allophycocyanin (clone L243,
BioLegend), anti-HLA-DQ antibody conjugated with
phycoerythrin (clone REA303, Miltenyi BIotec), or anti-HLA-
DP antibody conjugated with allophycocyanin (clone B7/21,
Leinco Technologies). Retroviral vectors encoding an E2-
Crimson fluorescent protein gene along with another set of
DRA1-P2A-DRB1, DQA1-P2A-DQB1, or DPA1-P2A-DPB1
gene cassettes were generated for each donor, and transduced
into K562 cells that have been transduced with the first set of DR,
DQ, or DP gene cassette, followed by sorting of cells expressing
E2-Crimson. For all subsequent experiments, lentiviral vectors
encoding a DRA1-P2A-DRB1, DQA1-P2A-DQB1, DPA1-P2A-
DPB1, DRA1-P2A-DRB3, or DRA1-P2A-DRB4 gene cassette
were generated and transduced into K562 cells (ATCC CCL-243)
using a standard spinfection protocol with viral supernatant
produced from 293FT cells (Thermo Fisher Scientific).
Expressions of HLA molecules were analyzed using the
antibodies described above. Over 97% of cells in all cell lines
except the combinations of DQA1*01:01 & DQB1*03:02 and
DQA1*03:01 & DQB1*05:01 (DQ trans-combinations of donor
nPOD 6342) were stained with the antibodies, and therefore no
sorting was needed. K562 cells transduced with the two HLA
allele combinations above failed to express HLA molecules on
cell surface. This observation was consistent with a previous
report characterizing preferred and failed HLA alpha and beta
chain combinations (60), and therefore these two trans-
combinations were excluded from analysis of TCRs derived
from the nPOD 6342 donor.
Determining HLA Restrictions
TCR transductants (20,000 cells per well) were cultured with an
optimal 15-mer peptide (100 µM) in the presence of K562 cells
expressing appropriate HLA molecules (50,000 cells per well) in
a well of round-bottom 96-well-plates. Peptide sequences used
for individual TCR transductant lines are included in Table 2.
HLA allele combinations used for individual assays are
designated in figure legends. After overnight culture, cells were
harvested and analyzed for ZsGreen-1 expression using a flow
cytometer (Cytoflex, Beckman Coulter) and FlowJo (BD) (38).
Cells cultured in the presence or absence of 5 µg/ml of anti-
mouse CD3ϵ antibody (Clone 125-2C11, BD) were included in
an assay as positive and negative controls, respectively. For the
TCR clonotype 55.C10, TCR transductants (20,000 cells per well)
were cultured with the cognate peptide (100 µM) in the presence
of an EBV-transformed cell line generated from nPOD 6414
spleen cells with or without anti-HLA-DR antibody (clone L243,
BD), anti-HLA-DQ antibody (generated in the Michels
laboratory), or HLA-DP antibody (clone B7/21, Abcam) at 1
µM, followed by analysis of ZsGreen-1 expression next day.
Dose–Response Assessment
TCR transductants (20,000 cells per well) were cultured with a
peptide designated in Table 2 at different concentrations (10 pM,
100 pM, 1 nM, 10 nM, 100 nM, 1 µM, 10 µM, and 100 µM) in the
presence of K562 cells expressing HLA molecules designated in
figure legends (50,000 cells per well), followed by analysis of
ZsGreen-1 expression next day. Peptide sequences tested for the
response by TCRs HA1.17 and 489 are PKYVKQNTLKLAT
(influenza HA:306–318), SGQGSFQPSQQNP (native a-gliadin),
and SGEGSFQPSQENP (deamidated a-gliadin p1E,p9E). EC50
values were calculated using Prism 8 (GraphPad), the nonlinear
regression log (agonist) vs. response (three parameters) equation
model. For TCR clonotypes, 6.G4 and 23.G8, EC50 values were
Landry et al. Proinsulin-Reactive Islet CD4 T Cells
Frontiers in Endocrinology | www.frontiersin.org March 2021 | Volume 12 | Article 62264712
not determined due to weak responses, and therefore the
nonlinear regression log (agonist) vs. normalized response
equation model was used to determine EC50 values.
Responses to Proinsulin and Human
Islet Lysates
Primary islet tissues isolated from non-diabetic organ donors
were obtained from the Integrated Islet Distribution Program
(IIDP). Islet lysates were generated by three steps of extractions
using trifluoroacetic acid, ammonium bicarbonate, and
trifluoroethanol. Extracts were lyophilized and dissolved in
urea. K562 cells expressing cognate HLA molecules for each
TCR clonotype (50,000 cells per well) were cultured with
proinsulin (Amidebio LLC, Louisville, CO) at 200 µg/ml or
lysates generated from 600-1600 IEQs of primary islets
overnight. TCR transductants (20,000 cells per well) were
directly added to culture wells containing K562 cells pulsed
with proinsulin or islet lysates, followed by analysis of
ZsGreen-1 expression next day.
Responses to Native and Citrullinated
Peptides
TCR transductants (20,000 cells per well) were cultured with native
insulin B-chain peptide (SHLVEALYLVCGE-R-GFFYTPK) or a
citrullinated insulin B-chain peptide (SHLVEALYLVCGE-Cit-
GFFYTPK) at different concentrations (100 pM, 1 nM, 10 nM,
100 nM, 1 µM, and 10 µM) in the presence of K562 cells expressing
HLAmolecules designated in figure legends (50,000 cells per well),
followed by analysis of ZsGreen-1 expression next day.
Computational Simulation of Predicting
Core Epitopes
The IEDB MHC-II Binding Prediction online tool (http://tools.
iedb.org/mhcii/) was used to predict core epitopes. Up to five 15-
mers of peptides that were contained in peptide pools
stimulating individual TCR transductants were analyzed using
the IEDB recommended prediction 2.22 method for binding to
cognate HLA molecules.
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